Department of Health & Ageing You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your tenure? Prime Minister Gillard announced during the last election in 2010 that both mental health reform and aged care reform…
Boehringer Ingelheim Benelux Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period of strong growth for the company based on the portfolio which we had. Today, however, following a strong focus on…
TiGenix - Belgium Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to make such a dramatic and bold shift in your professional life? I was young and ambitious and despite having a…
Amgen Belgium Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is a relatively young biotechnology company with just over 30 years of experience in the industry. Amgen entered the Belgian market…
Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…
Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…
Amgen Czech Republic Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us as a ‘wild’ time, with little regulation and easy growth. Since then, the Czech pharma market became much more complex…
FeBelGen Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing the generic and biosimilar drugs industry in Belgium? When I started to head FeBelGen in 2006, my goal/objective was –…
Cegedim Czech Republic Mr. Krýza, Mr. Nádvorník, between the two of you, you have over 21 years of experience at Cegedim, and have watched this company grow significantly through a series of mergers. What has been the historical development of the Czech affiliate? Tomáš Nádvorník: Cegedim was established in the Czech Republic in…
Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…
National Agency for Medicines and Medical Devices (NAMMD) of Romania Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s pharmaceutical market. Over these five decades, thorough changes in the political regime, subsequent regulatory changes, the emergence of new institutions, and many other factors have drastically changed…
See our Cookie Privacy Policy Here
